Lynparza PFS tops expectations in SOLO-2

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Lynparza olaparib showed a significant progression-free survival benefit vs. placebo in the Phase III SOLO-2 trial to treat BRCA-mutated metastatic ovarian cancer. The pharma said

Read the full 309 word article

User Sign In